Advances in Bile Acid Metabolites and Their Receptor-Targeted Interventions in Chronic Kidney Disease
DOI:
https://doi.org/10.70088/8ksgw627Keywords:
bile acids, chronic kidney disease, gut-kidney axis, farnesoid X receptor (FXR), G protein-coupled bile acid receptor 1 (TGR5)Abstract
Chronic kidney disease (CKD) has traditionally been understood from a glomerular perspective: proteinuria and a decline in estimated glomerular filtration rate (eGFR) are regarded as core hallmarks of the disease, and current intervention options for CKD are limited.Recent studies have highlighted the critical role of the gut-kidney axis in the pathogenesis and management of CKD; metabolomics has shown that the accumulation of conjugated bile acids is associated with declining renal function and cardiovascular risk, whereas elevated levels of primary bile acids are associated with a lower risk of the disease.Research data, primarily from animal and cell culture models, indicate that bile acids (BAs) can influence CKD through the nuclear farnesoid X receptor (FXR) and the membrane G protein-coupled bile acid receptor (TGR5),This article provides a systematic review centered on the gut-kidney-vascular axis mediated by bile acid metabolites, elucidating the mechanisms of bile acid homeostasis remodeling and tissue damage in CKD, and highlighting that disease modification requires simultaneous targeting of specific bile acid subtypes and their receptors, rather than relying solely on existing therapies.References
A. S. Levey et al., "The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report," Kidney Int., vol. 80, no. 1, pp. 17–28, Jul. 2011.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group, "KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)," Kidney Int. Suppl. (2011), vol. 7, no. 1, pp. 1–59, Jul. 2017.
GBD 2021 Diseases and Injuries Collaborators, "Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021," Lancet, vol. 403, no. 10440, pp. 2133–2161, May 18, 2024.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group, "KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease," Kidney Int., vol. 105, no. 4S, pp. S117–S314, Apr. 2024.
Y. Y. Chen et al., "Microbiome-metabolome reveals the contribution of the gut-kidney axis to kidney disease," J. Transl. Med., vol. 17, no. 1, p. 5, Jan. 3, 2019.
S. Bhargava, E. Merckelbach, H. Noels, A. Vohra, and J. Jankowski, "Homeostasis in the Gut Microbiota in Chronic Kidney Disease," Toxins (Basel), vol. 14, no. 10, p. 648, Sep. 20, 2022.
J. Aron-Wisnewsky, M. V. Warmbrunn, M. Nieuwdorp, and K. Clément, "Metabolism and Metabolic Disorders and the Microbiome: The Intestinal Microbiota Associated With Obesity, Lipid Metabolism, and Metabolic Health-Pathophysiology and Therapeutic Strategies," Gastroenterology, vol. 160, no. 2, pp. 573–599, Jan. 2021.
K. Hou et al., "Microbiota in health and diseases," Signal Transduct. Target. Ther., vol. 7, no. 1, p. 135, Apr. 23, 2022.
C. D. Fuchs and M. Trauner, "Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology," Nat. Rev. Gastroenterol. Hepatol., vol. 19, no. 7, pp. 432–450, Jul. 2022.
H. Lun et al., "Altered gut microbiota and microbial biomarkers associated with chronic kidney disease," Microbiology Open, vol. 8, no. 4, p. e00678, Apr. 2019.
J. Yang, M. Pontoglio, and F. Terzi, "Bile Acids and Farnesoid X Receptor in Renal Pathophysiology," Nephron, vol. 148, no. 9, pp. 618–630, 2024.
D. Wang et al., "Characterization of gut microbial structural variations as determinants of human bile acid metabolism," Cell Host Microbe, vol. 29, no. 12, pp. 1802–1814.e5, Dec. 8, 2021.
T. Li and J. Y. Chiang, "Bile acid signaling in metabolic disease and drug therapy," Pharmacol. Rev., vol. 66, no. 4, pp. 948–983, Oct. 2014.
J. C. Poland and C. R. Flynn, "Bile Acids, Their Receptors, and the Gut Microbiota," Physiology (Bethesda), vol. 36, no. 4, pp. 235–245, Jul. 1, 2021.
B. V. Jones, M. Begley, C. Hill, C. G. Gahan, and J. R. Marchesi, "Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome," Proc. Natl. Acad. Sci. U.S.A., vol. 105, no. 36, pp. 13580–13585, Sep. 9, 2008.
G. Le Martelot et al., "REV-ERBalpha participates in circadian SREBP signaling and bile acid homeostasis," PLoS Biol., vol. 7, no. 9, p. e1000181, Sep. 2009.
S. L. Collins, J. G. Stine, J. E. Bisanz, C. D. Okafor, and A. D. Patterson, "Bile acids and the gut microbiota: metabolic interactions and impacts on disease," Nat. Rev. Microbiol., vol. 21, no. 4, pp. 236–247, Apr. 2023.
A. Wahlström, S. I. Sayin, H. U. Marschall, and F. Bäckhed, "Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism," Cell Metab., vol. 24, no. 1, pp. 41–50, Jul. 12, 2016.
S. A. Moser and D. C. Savage, "Bile salt hydrolase activity and resistance to toxicity of conjugated bile salts are unrelated properties in lactobacilli," Appl. Environ. Microbiol., vol. 67, no. 8, pp. 3476–3480, Aug. 2001.
T. Li and J. Y. Chiang, "Nuclear receptors in bile acid metabolism," Drug Metab. Rev., vol. 45, no. 1, pp. 145–155, Feb. 2013.
L. N. Lucas et al., "Investigation of bile salt hydrolase activity in human gut bacteria reveals production of conjugated secondary bile acids," Nat. Commun., 2026.
M. Zhao et al., "The bile acid-gut microbiota axis: A central hub for physiological regulation and a novel therapeutic target for metabolic diseases," Biomed. Pharmacother., vol. 188, pp. 118–182, Jul. 2025.
N. van Best et al., "Bile acids drive the maturation of the newborn’s gut microbiota," Nat. Commun., vol. 11, no. 1, p. 3692, Jul. 23, 2020.
K. Panzitt and M. Wagner, "FXR in liver physiology: Multiple roles in regulating liver metabolism," Biochim. Biophys. Acta Mol. Basis Dis., vol. 1867, no. 7, p. 166133, Jul. 1, 2021.
K. M. Anderson and C. P. Gayer, "The Pathophysiology of Farnesoid X Receptor (FXR) in the GI Tract: Inflammation, Barrier Function, and Innate Immunity," Cells, vol. 10, no. 11, p. 3206, Nov. 17, 2021.
S. Fiorucci, E. Distrutti, A. Carino, A. Zampella, and M. Biagioli, "Bile acids and their receptors in metabolic disorders," Prog. Lipid Res., vol. 82, p. 101094, Apr. 2021.
X. Zhang et al., "Farnesoid X receptor (FXR) gene deficiency impairs urine concentration in mice," Proc. Natl. Acad. Sci. U.S.A., vol. 111, no. 6, pp. 2277–2282, Feb. 11, 2014.
V. Massafra, R. Pellicciari, A. Gioiello, and S. W. C. van Mil, "Progress and challenges of selective Farnesoid X Receptor modulation," Pharmacol. Ther., vol. 191, pp. 162–177, Nov. 2018.
S. Li, C. Li, and W. Wang, "Bile acid signaling in renal water regulation," Am. J. Physiol. Renal Physiol., vol. 317, no. 1, pp. F73–F76, Jul. 1, 2019.
X. X. Wang et al., "The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria," Am. J. Physiol. Renal Physiol., vol. 297, no. 6, pp. F1587–F1596, Dec. 2009.
D. Jing et al., "Obeticholic acid ameliorates sepsis-induced renal mitochondrial damage by inhibiting the NF-κB signaling pathway," Ren. Fail., vol. 46, no. 2, p. 2368090, Dec. 2024.
W. Lun et al., "Mechanism of action of the bile acid receptor TGR5 in obesity," Acta Pharm. Sin. B, vol. 14, no. 2, pp. 468–491, Feb. 2024.
S. Zhou et al., "TGR5 rescues renal ischemia-reperfusion injury by suppressing ferroptosis and the cAMP/PKA/Nrf2 axis," Eur. J. Pharmacol., vol. 1015, p. 178597, Feb. 15, 2026.
B. Guan et al., "Bile acid coordinates microbiota homeostasis and systemic immunometabolism in cardiometabolic diseases," Acta Pharm. Sin. B, vol. 12, no. 5, pp. 2129–2149, May 2022.
W. Jin, M. Zheng, Y. Chen, and H. Xiong, "Update on the development of TGR5 agonists for human diseases," Eur. J. Med. Chem., vol. 271, p. 116462, May 5, 2024.
M. Nagata, "Podocyte injury and its consequences," Kidney Int., vol. 89, no. 6, pp. 1221–1230, Jun. 2016.
J. B. Kopp et al., "Podocytopathies," Nat. Rev. Dis. Primers, vol. 6, no. 1, p. 68, Aug. 13, 2020.
P. Rachubik et al., "Role of bile acid-dependent Takeda G-coupled protein receptor 5 (TGR5) in regulating AMPK expression in human podocytes," Biochem. Biophys. Res. Commun., vol. 759, p. 151671, May 20, 2025.
Y. Guo, T. Luo, G. Xie, and X. Zhang, "Bile acid receptors and renal regulation of water homeostasis," Front. Physiol., vol. 14, p. 1322288, Nov. 15, 2023.
Y. Guo et al., "Activation of TGR5 Increases Urine Concentration by Inducing AQP2 and AQP3 Expression in Renal Medullary Collecting Ducts," Kidney Dis. (Basel), vol. 10, no. 3, pp. 181–192, Mar. 5, 2024.
M. Ishizawa, D. Akagi, and M. Makishima, "Lithocholic Acid Is a Vitamin D Receptor Ligand That Acts Preferentially in the Ileum," Int. J. Mol. Sci., vol. 19, no. 7, p. 1975, Jul. 6, 2018.
I. Aggeletopoulou, K. Thomopoulos, A. Mouzaki, and C. Triantos, "Vitamin D-VDR: Novel Anti-Inflammatory Molecules-New Insights into Their Effects on Liver Diseases," Int. J. Mol. Sci., vol. 23, no. 15, p. 8465, Jul. 30, 2022.
M. Dutta, J. J. Lim, and J. Y. Cui, "Pregnane X Receptor and the Gut-Liver Axis: A Recent Update," Drug Metab. Dispos., vol. 50, no. 4, pp. 478–491, 2022.
E. Studer et al., "Conjugated bile acids activate the sphingosine-1-phosphate receptor 2 in primary rodent hepatocytes," Hepatology, vol. 55, no. 1, pp. 267–276, Jan. 2012.
H. Chen et al., "Sphingosine 1-phosphate receptor: a new therapeutic direction for various diseases," Biomed. Pharmacother., vol. 153, p. 113341, Sep. 2022.
S. Stern, R. Kurian, and H. Wang, "Clinical Relevance of the Constitutive Androstane Receptor," Drug Metab. Dispos., vol. 50, no. 7, pp. 1010–1018, Jul. 2022.
M. Provenzano, G. Coppolino, T. Faga, C. Garofalo, R. Serra, and M. Andreucci, "Epidemiology of cardiovascular risk in patients with chronic kidney disease: the real silent killer," Rev. Cardiovasc. Med., vol. 20, no. 4, pp. 209–220, Dec. 30, 2019.
N. Y. Mansour et al., "Serum metabolomics identifies gut-derived uremic toxins and bile acid dysregulation associated with chronic kidney disease severity," Sci. Rep., vol. 16, no. 1, p. 12375, Apr. 14, 2026.
Y. Xin et al., "Multi-omics reveal the key role of gut microbiota metabolism in adenine-induced chronic kidney disease," Toxicol. Appl. Pharmacol., vol. 509, p. 117754, Apr. 2026.
J. C. Rowe, S. C. Summers, J. M. Quimby, and J. A. Winston, "Fecal bile acid dysmetabolism and reduced ursodeoxycholic acid correlate with novel microbial signatures in feline chronic kidney disease," Front. Microbiol., vol. 15, p. 1458090, Oct. 21, 2024.
T. Geng et al., "Circulating concentrations of bile acids and prevalence of chronic kidney disease among newly diagnosed type 2 diabetes patients: a cross-sectional study," Nutr. J., vol. 23, no. 1, p. 28, Mar. 2, 2024.
L. M. Liu et al., "Ureic clearance granule ameliorates chronic kidney disease by reshaping microbial dysbiosis via modulating bile acid metabolism," Chin. Med., vol. 21, no. 1, p. 155, May 29, 2026.
G. Song et al., "Bile acids affect intestinal barrier function through FXR and TGR5," Front. Med. (Lausanne), vol. 12, p. 1607899, Jul. 7, 2025.
T. Speer, S. Dimmeler, S. J. Schunk, D. Fliser, and P. M. Ridker, "Targeting innate immunity-driven inflammation in CKD and cardiovascular disease," Nat. Rev. Nephrol., vol. 18, no. 12, pp. 762–778, Dec. 2022.
Y. Guo, G. Xie, and X. Zhang, "Role of FXR in Renal Physiology and Kidney Diseases," Int. J. Mol. Sci., vol. 24, no. 3, p. 2408, Jan. 26, 2023.
B. A. Jones et al., "Farnesoid X receptor prevents neutrophil extracellular traps via reduced sphingosine-1-phosphate in chronic kidney disease," Am. J. Physiol. Renal Physiol., vol. 325, no. 6, pp. F792–F810, Dec. 1, 2023.
H. Lang et al., "Roux-en-Y gastric bypass alleviates kidney inflammation and improves kidney function in db/db mice by activating the TLCA/TGR5 pathway," Am. J. Physiol. Endocrinol. Metab., vol. 328, no. 2, pp. E148–E160, Feb. 1, 2025.
X. X. Wang et al., "Activation of the G Protein-Coupled Bile Acid Receptor TGR5 Inhibits Kidney Disease in Obesity and Diabetes," J. Am. Soc. Nephrol., vol. 27, no. 5, pp. 1362–1378, May 2016.
X. Yang et al., "Bile Acid Receptor Agonist Reverses Transforming Growth Factor-β1-Mediated Fibrogenesis in Human Induced Pluripotent Stem Cell-Derived Kidney Organoids," Lab. Invest., vol. 104, no. 5, p. 100336, May 2024.
M. Liu et al., "Schaftoside alleviates HFD-induced hepatic lipid accumulation in mice via upregulation of the farnesoid X receptor," J. Ethnopharmacol., vol. 255, p. 112776, Jun. 12, 2020.
D. Song et al., "Wen-Shen-Jian-Pi-Hua-Tan decoction protects against early obesity-related glomerulopathy by improving renal bile acid composition and suppressing lipogenesis, inflammation, and fibrosis," Phytomedicine, vol. 116, p. 154861, Jul. 25, 2023.
R. Li et al., "Targeted metabolomics study of serum bile acid profile in patients with end-stage renal disease undergoing hemodialysis," PeerJ, vol. 7, p. e7145, Jun. 17, 2019.
J. Rysz, B. Franczyk, J. Ławiński, R. Olszewski, A. Ciałkowska-Rysz, and A. Gluba-Brzózka, "The Impact of CKD on Uremic Toxins and Gut Microbiota," Toxins (Basel), vol. 13, no. 4, p. 252, Mar. 31, 2021.
J. Hou et al., "Gut–liver–kidney axis: A systems biology framework for understanding and treating chronic kidney disease (Review)," Int. J. Mol. Med., vol. 58, no. 4, p. 266, Oct. 2026.
B. Opdebeeck, P. C. D'Haese, and A. Verhulst, "Molecular and Cellular Mechanisms that Induce Arterial Calcification by Indoxyl Sulfate and P-Cresyl Sulfate," Toxins (Basel), vol. 12, no. 1, p. 58, Jan. 19, 2020.
F. Liu, Y. Liang, and X. Lin, "MiR-151b inhibits osteoblast differentiation via downregulation of Msx2," Connect. Tissue Res., vol. 63, no. 2, pp. 112–123, Mar. 2022.
S. Miyazaki-Anzai et al., "Free Deoxycholic Acid Exacerbates Vascular Calcification in CKD through ER Stress-Mediated ATF4 Activation," Kidney360, vol. 2, no. 5, pp. 857–868, May 2021.
W. Zou et al., "Metformin attenuates high glucose-induced injury in islet microvascular endothelial cells," Bioengineered, vol. 13, no. 2, pp. 4385–4396, Feb. 2022.
J. Xue et al., "Farnesoid X receptor-dependent microbiome-bile acid signaling mediates obstructive sleep apnea-induced atherosclerosis," bioRxiv [Preprint], 2026.03.31.715631, Apr. 1, 2026.
W. Chen et al., "Aging-driven metabolic abnormalities remodel intercellular communication through the gut-liver-heart axis and may promote coronary artery disease: the key role of bile acid metabolism," Front. Immunol., vol. 17, p. 1870980, Jul. 6, 2026.
S. Marchianò et al., "Atorvastatin protects against liver and vascular damage in a model of diet-induced steatohepatitis by resetting FXR and GPBAR1 signaling," FASEB J., vol. 36, no. 1, p. e22060, Jan. 2022.
Y. Iwashita et al., "Dietary Changes Involving Bifidobacterium longum and Other Nutrients Delay the Progression of Chronic Kidney Disease," Am. J. Nephrol., vol. 47, no. 5, pp. 325–332, 2018.
K. E. Adair and R. G. Bowden, "Ameliorating Chronic Kidney Disease Using a Whole Food Plant-Based Diet," Nutrients, vol. 12, no. 4, p. 1007, Apr. 6, 2020.
P. Molina, E. Gavela, B. Vizcaíno, E. Huarte, and J. J. Carrero, "Optimizing Diet to Slow CKD Progression," Front. Med. (Lausanne), vol. 8, p. 654250, Jun. 25, 2021.
A. De Mauri et al., "Probiotics-Supplemented Low-Protein Diet for Microbiota Modulation in Patients with Advanced Chronic Kidney Disease (ProLowCKD): Results from a Placebo-Controlled Randomized Trial," Nutrients, vol. 14, no. 8, p. 1637, Apr. 14, 2022.
K. Makki et al., "6α-hydroxylated bile acids mediate TGR5 signaling to improve glucose metabolism upon dietary fiber supplementation in mice," Gut, vol. 72, no. 2, pp. 314–324, Feb. 2023.
P. D. Cotter, C. Hill, and R. P. Ross, "Bacteriocins: developing innate immunity for food," Nat. Rev. Microbiol., vol. 3, no. 10, pp. 777–788, Oct. 2005.
N. Stepanova, "Probiotic interventions in peritoneal dialysis: A review of underlying mechanisms and therapeutic potentials," World J. Nephrol., vol. 13, no. 4, pp. 98719, Dec. 25, 2024.
X. Wang et al., "Aberrant gut microbiota alters host metabolome and impacts renal failure in humans and rodents," Gut, vol. 69, no. 12, pp. 2131–2142, Dec. 2020.
C. Y. Yang et al., "Synbiotics Alleviate the Gut Indole Load and Dysbiosis in Chronic Kidney Disease," Cells, vol. 10, no. 1, p. 114, Jan. 9, 2021.
S. Y. Han et al., "Farnesoid X receptor (FXR) agonist ameliorates systemic insulin resistance, dysregulation of lipid metabolism, and alterations in various organs in a type 2 diabetic kidney animal model," Acta Diabetol., vol. 58, no. 4, pp. 495–503, Apr. 2021.
J. Liu et al., "Efficacy and safety of Zicuiyin decoction for diabetic kidney disease: A multicenter, randomized controlled trial," Phytomedicine, vol. 100, p. 154079, Jun. 2022.
W. Zhou et al., "The gut microbe Bacteroides fragilis ameliorates renal fibrosis in mice," Nat. Commun., vol. 13, no. 1, p. 6081, Oct. 14, 2022.
C. M. Surawicz et al., "Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections," Am. J. Gastroenterol., vol. 108, no. 4, pp. 478–498, Apr. 2013.
J. Bian, A. Liebert, B. Bicknell, X. M. Chen, C. Huang, and C. A. Pollock, "Fecal Microbiota Transplantation and Chronic Kidney Disease," Nutrients, vol. 14, no. 12, p. 2528, Jun. 17, 2022.
Z. B. Hu et al., "Dysbiosis of the intestinal microbiota mediates tubulointerstitial injury in diabetic nephropathy via the disruption of cholesterol homeostasis," Theranostics, vol. 10, no. 6, pp. 2803–2816, Feb. 3, 2020.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Yi You, Jiangwa Xing, Mingxiao Wang (Author)

This work is licensed under a Creative Commons Attribution 4.0 International License.









